In the 4 patients who received the 400 mg per week dose, ATL1103 reduced sIGF-I levels consistently and by an average (mean) of 30% (range 4% to 48%) at week 14 (one week past the last dose) which is the primary efficacy time point for the trial. sIGF-I levels were reduced by a mean of 38% (28 – 48%) in the 3 patients who had lower body weights (58 - 83 kg at screening) and thereby received a relatively higher dose per kg bodyweight. The one patient showing the lowest sIGF-1 reduction at week 14 had the highest body weight (132 kg at screening).
- Forums
- ASX - By Stock
- PER
- results in!! you beauty!!!!
results in!! you beauty!!!!, page-2
-
- There are more pages in this discussion • 118 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add PER (ASX) to my watchlist
(20min delay)
|
|||||
Last
7.5¢ |
Change
-0.005(6.25%) |
Mkt cap ! $71.22M |
Open | High | Low | Value | Volume |
8.0¢ | 8.0¢ | 7.5¢ | $57.50K | 742.1K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 121681 | 7.8¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
7.9¢ | 11065 | 3 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 121681 | 0.078 |
1 | 20000 | 0.077 |
2 | 85000 | 0.076 |
4 | 591988 | 0.075 |
2 | 353708 | 0.074 |
Price($) | Vol. | No. |
---|---|---|
0.079 | 11065 | 3 |
0.080 | 118970 | 2 |
0.082 | 94978 | 1 |
0.085 | 106431 | 2 |
0.086 | 100000 | 1 |
Last trade - 11.29am 02/07/2024 (20 minute delay) ? |
Featured News
PER (ASX) Chart |